Biovitrum Initiates Clinical Phase II Study of Glaucoma Treatment
The Phase II study includes 150 patients with an elevated intraocular pressure (a hallmark of glaucoma) and is placebo-controlled. It is carried out at several clinics in both Sweden and Ukraine.
The current hypothesis is that BVT.28949 reduces intraocular pressure by stimulating the outflow of aqueous humor through a mechanism different from that of presently available products, which means that BVT.28949 could function as a monotherapy or as a combination alternative with existing products.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.